Fig. 3From: What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND studyAdjusted change in HbA1c 1 year after a limited response to a sulfonylurea (n = 3569) (a), thiazolidinedione (n = 3047) (b), or DPP4 inhibitor (n = 2558) (c) stratified by the treatment decision after response HbA1c: continue, switch, or addBack to article page